Clinical Trials Browser

Phase 1/2 × cemiplimab × Clear all

NCT07147231 2026-04-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04626635 2026-04-09

COMBINE-EGFR-1

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06162572 2026-04-03

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03491683 2026-03-19

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

Glioblastoma

NCT06384807 2026-03-11

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05125016 2026-02-27

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Phase 1/2 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05882734 2026-02-17

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT04913220 2026-02-04

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Phase 1/2 Terminated

46 enrolled 22 charts

Melanoma

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06923761 2026-01-28

EMITT-1

Phase 1/2 Recruiting

GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasms

NCT06413680 2025-12-15

BrILliance

Phase 1/2 Recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT03564340 2025-12-03

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04590326 2025-11-21

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT03972657 2025-11-06

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03769181 2025-09-23

A Study of Isatuximab-based Therapy in Participants With Lymphoma

Phase 1/2 Terminated

58 enrolled 37 charts

Lymphoma

NCT05259696 2025-08-20

GLIMMER-01

Phase 1/2 Completed

69 enrolled 13 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

NCT05538988 2025-06-27

BIOSELECT

Phase 1/2 Withdrawn

Mycosis Fungoides

NCT04305795 2025-06-19

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04706715 2025-05-31

LAG3 PET Imaging in Advanced Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT06088771 2025-05-08

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04339062 2025-04-23

CONTRAC

Phase 1/2 Completed

12 enrolled 13 charts

Cutaneous Squamous Cell Carcinoma

NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Phase 1/2 Terminated

57 enrolled 31 charts

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

NCT04382898 2025-03-20

PRO-MERIT

Phase 1/2 Terminated

75 enrolled 17 charts

Prostatic Neoplasms

NCT05662397 2025-02-04

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Phase 1/2 Active not recruiting

Neoplasms, Recurrence

NCT06090266 2025-01-07

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Phase 1/2 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1/2 Completed

109 enrolled 27 charts

Multiple Myeloma

NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Phase 1/2 Unknown

DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT03294083 2022-10-27

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, Neoplasms

NCT03367819 2022-05-16

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Phase 1/2 Terminated

44 enrolled 24 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT03684785 2022-04-07

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Phase 1/2 Terminated

Melanoma, Skin Neoplasms, Carcinoma, Merkel Cell